UPDATE: Editor-in-Chief States: ‘After Careful Examination of These Original Material, Neuroscience [Journal] Found No Evidence of Manipulation of the…

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. Youll have what you need to act in real-time before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Go here to read the rest:
UPDATE: Editor-in-Chief States: 'After Careful Examination of These Original Material, Neuroscience [Journal] Found No Evidence of Manipulation of the...

IIT-Gandhinagar Opens Application Process For PG Programmes In Cognitive Science, Society And Culture – NDTV

The application process will conclude on January 20

Image credit: IIT Gandhinagar Press Release

The Indian Institute of Technology (IIT Gandhinagar) is inviting applications for the post graduate (Masters) programmes in Cognitive Science, Society and Culture. The students can apply for the programmes on the official website- iitgn.ac.in. For M.Sc (Cognitive Science) programme, students have to apply on the official website- cogs.iitgn.ac.in/cogs-msc and for MA (Society and Culture), apply at hss.iitgn.ac.in/masc.

The application process will conclude on January 20. "Due to the COVID-19 pandemic, both admission tests and interviews for the courses will be conducted online. Applications for these two courses can be obtained from the following link - admissions.iitgn.ac.in/pgadmission," the release mentioned. The entrance exam and interviews will be conducted online due to Covid-19, the dates of which will be informed later.

The M.Sc in Cognitive Science will cover industry roles such as Educators, User Experience (UX), Linguistic analysts, Data analysts, Product developers/designers, AI engineers, Cognitive rehabilitation, Robotics, consumer behaviour etc, academic roles- Teaching or Research in, Human-Computer Interface, Neuroscience, Decision Making, etc. and International Ph.D. in opportunities.

In the MA programme in Society and Culture, the students will get familiar with academic roles such as Teaching or Research in Ecological Sciences and Public Policy, among others, and industry roles- Journalism, Advertising/media, Communications, Writing, Human resources. The students will also get an opportunity to do doctorate (Ph.D.) from varsity abroad and work with non-profit organisations (NGOs). "The M.A. in Society and Culture provides for fundamental learning, debates, and methods in the disciplines of literature, sociology, anthropology, political science, and history. The two-year masters program emerges from a conviction that students need to be trained to understand the social and political context they are part of," the release mentioned.

Prof Jaison. A. Manjaly, Head, Discipline of Humanities and Social Sciences, IIT Gandhinagar, said, The interdisciplinary nature of all the courses at IIT Gandhinagar makes a student's learning experience highly enriching. The M.A. in Society and Culture offers students diverse perspectives on social and cultural factors with a nuanced and more in-depth understanding of their context. The M.Sc. in Cognitive Science, on the other hand, offers a deeper understanding of mind, brain, and cognition. These programs are also uniquely aligned to the IITGN's vision to enable lifelong learning among the students.

The candidates required financial assistance can apply for 'On-Campus Employment Opportunities Program. "The Institute also encourages the M.Sc. (Cognitive Science) and M.A. (Society and Culture) students to present their research work at national and international conferences, and provides travel scholarships of up to Rs. 60,000," the release read.

In both programs, students will have unique research experiences like conducting field-work, conducting ethnographic research in the old city of Ahmedabad, visiting historical and archeological sites in Gujarat, conducting experiments in the state of the art cognitive science lab, traveling across the country through the IIT Gandhinagar Explorer Fellowships, taking advantage of the national and international academic and industrial internship opportunities and much more. Exposure to international faculty is another highlight of these programs, it mentioned.

Cognitive Science is a fast-growing emerging field that works at the intersection of philosophy, psychology, computer science, neuroscience, and Artificial Intelligence while the Society and Culture program provides exposure to key disciplines within the Humanities and Social Sciences including, history, culture studies, literature, translation studies, sociology, political science and anthropology. For details, please visit the website- iitgn.ac.in.

Read the rest here:
IIT-Gandhinagar Opens Application Process For PG Programmes In Cognitive Science, Society And Culture - NDTV

Promoting Love and Peace Across Generations through Science and Global Partnerships – Yale School of Medicine

The environmental influence on a childs social, emotional, and cognitive development is undeniable. Unfortunately, almost half of our worlds children are at risk of not reaching their full developmental potential. The COVID-19 pandemic has been difficult for everyone, but little is known about the long-term adverse impact this may have on the worlds most vulnerable children currently living in countries with ongoing threats of violence, displacement, and conflict. Unfortunately, much of these dangers have been exacerbated by the pandemic. Peacebuilding initiatives, particularly during the early childhood years, are more important than ever as the international community prepares to navigate a post-pandemic world.

When looking for contributors to a special issue tackling the concepts of Love and Fear in the medical journal Comprehensive Psychoneuroendocrinology, Sue Carter, Distinguished University Scientist and Rudy Professor Emerita of Biology at Indiana University, and an expert in the endocrinology of love, reached out to Dr. James F. Leckman, Neison Harris Professor in the Yale Child Study Center and Professor of Pediatrics, to provide insight into the importance of early childhood peacebuilding initiatives that target young children and their families.

Dr. Leckman assembled a team of experts and practitioners in the field of early childhood development (ECD) and peacebuilding around the globe including notable colleagues from Yale University and the Early Childhood Peace Consortium (ECPC) to partner with for this special journal issue. Yale contributors consist of Dr. James F. Leckman, Catherine Panter-Brick, Ph.D., Angelica Ponguta, Ph.D., M.P.H., Rima Salah, Ph.D., Franz J. Hartl, J.D., Michael F. McCarthy, M.A., and N. Shemrah Fallon. This international collaboration resulted in the seminal paper Love and Peace Across Generations: Biobehavioral Systems and Global Partnerships.

The paper emphasizes the importance of the early childhood years on a persons lifelong development, a focus that was widely championed by Yale Professor Emeritus of Psychology, the late Edward Zigler, widely known as the founding father of Head Start who was a pioneer in the field of early childhood development, and a champion for the rights of children. The paper outlines in detail, the link between neuroscience and peacebuilding, particularly the influence that neuropeptides have in influencing social interactions, attachment, love, fear, trauma, compassion, and empathy. The paper also specifies the role of parents in providing nurturing environments. Furthermore, the authors highlight successful early childhood development initiatives that have been implemented in conflict-affected countries as well as argue that it is imperative for our next generation of youth to play an active and leading role in peacebuilding initiatives.

The authors call on the international community to address four key action points that support young children and their families:

The open access journal article is available to the public and can be downloaded along with the complete special journal issue.

Link:
Promoting Love and Peace Across Generations through Science and Global Partnerships - Yale School of Medicine

NESTRE Believes Sport Performance Is From the Neck Up and Aims to Train the Mind and Brain Accordingly – SportTechie

Our Startups series looks at companies and founders who are innovating in the fields of athlete performance, fan engagement, team/league operations and other high-impact areas in sports. If youd like to be considered for this series, tell us about your mission.

* * * * *

Worlds shortest elevator pitch: NESTRE combines neuroscience, performance and AI machine learning to help people get mentally and cognitively better.

Company: NESTRE

Location: Orlando, Florida

Year founded: 2018

Website/App: https://nestreperformance.com/Funding round to date: Pre-Seed. We will be going into a Seed Round probably in Q2, but we're currently in Pre-Seed funding. Were in a bridge funding round right now.

Who are your investors? Weve raised $1.6 million. Investors include Pro Football Hall of Fame wide receiver Calvin Johnson Jr. and former Lions teammate Rob Sims. Toby Redshaw, former VP of Verizon 5G and Infoworld Top 25 Global CTO and Information Week Top 50 Global CIO. The Minority Entrepreneur Institute. Florcy Morisset, former strategy lead at Netflix and Dell Technologies. Moaz Hamid, formerly with Palm Inc., Microsoft and Google, now Founder and Managing Partner of mvm Ventures. Former Nike executive Mark Hochgesang, of Oregon Sports Angels, as well as global sports and health tech accelerator, leAD Sports, and global real estate developer and owners of Tottenham, Tavistock.

Are you looking for more investment? Yes.

Tell us about yourself, CEO & Founder Dr. Tommy Shavers: I was born in Niagara Falls, N.Y., raised in South Florida. Igrew up loving sports and loving learning. I played college football at the University of Central Florida, was ateamcaptain.Had the unfortunate experience of suffering several head injuries that ended my playing career, and also experienced, as a result, severe cognitive impairment and decline for several years. I was told by my doctor those things don't get better--they only get worse. This was around the time when conversations around CTE were becoming apparent. I chose not to give in to that narrative and created a model for self-recovery. I started with the premise: If the brain can be injured, it serves to reason that it functions like a muscle. And if it functions like a muscle, it serves to reason it could be rehabbed. I created my own cognitive conversion model and self-recovered, I had the opportunity to share this at a global health catalyst summit at Harvard. That became the seed and catalyst for NESTRE, my vision and dedication to help people know they can get better. And not just from mental and cognitive challenges, but the opportunities to increase the mental and cognitive performance. I really got inspired by the neuroscience of neuroplasticity and connected with some of the world's top experts and formed NESTRE. That's our focus, mission and passionto help build a better world with the human in mind. We've yet to tap into our human wellness and performance potential.

Who are your co-founders/partners? Right now, Julius Thomas is a partner but hes about to take on the role as co-founder. Julius [former NFL tight end] has an incredible story. Retired from the game, really still somewhat in his prime, to pursue his personal passion of helping people get better and increase quality of life from mental and cognitive perspectives. He pursued a Doctorate in psychology with a focus on mental health and neuroscience, and he's been an incredible partner along the way in the work we've done.

Former Pro Bowl tight end Julius Thomas is a NESTRE partner who has pursued a doctorate in psychology with a focus on mental health and neuroscience.

How does your product/service work? The NESTRE app, the vision is: we want it to essentially create the first digital environment for people to better both their mind and braingiving users access to the world of neuroscience and AI machine learning to help them get better, perform better and feel better. As I said, the purpose of the app is creating a digital experience to better both the mind and the brain. From the sports perspective, its understanding how mental wellness and cognitive performance are core aspects of the sports and performance world. We're really leveraging our experience and expertise in the sports world, mental wellness and neuroscience, really to take it to the next level, as mental health and cognitive performance are becoming core focuses in the performance space.

What problem is your company solving? If you look around the sports world, the mental health challenges that have been apparent, some of the athletes weve seen, the narrative has typically been either a fatalistic or stigmatized narrative or it's been a siloed narrative. Performance-based has typically been focusing on the neck down. What we're looking to do is really to change the narrative and shift the paradigm when it comes to mental and cognitive strength training. That mental health and cognitive performance are really integrated, and we all need the opportunity to get better and be stronger in these areas. Our first and most important workout really starts with the neck up. We really want to change this narrative about mental and cognitive capacity, performance, wellness, and really say, This is the first strength training that is a value to everyone when it comes to development, wellness, performance and desired outcomes.

What does your product cost and who is your target customer? We have a freemium subscription, and a B2B, B2C model from $9.99 to $79.99 annually. We also have a B2B partnership service model. We break our customers into three segments: the required performer, the desired performer and the everyday performing population. For us, its being able to target all three of these groups, whether it's someone wanting to recover their mental and cognitive dynamics or enhance their ability to perform better or just everyday performance sports individuals. The piece that's important for us is we really see life. Sports are performance. Everyday life is a performance. We're also leveraging the core aspects of sports, not just at the highest level, but at every level. That's how we break the world down into the world of performers because we're all performing on an everyday basis.

How are you marketing your product? We spent a lot of time over the last couple of years really building a strategic network. As we look at our go-to-market strategy, really leveraging our network relationships in the wellness, sports and performance world with Calvin Johnson and our other athletes that are investors. And, really, the halo effect of the relationships we have, with professional athletes to professional organizations, combined with strategic performance marketing and an organic growth strategy, is really how we're looking to get our product to market. We've been building that over the last couple of years, as we look to move that forward with some of these partnerships we have.

NFL Hall of Famer Calvin Johnson, the former Detroit Lion known as 'Megatron,' is a key investor in NESTRE.

How do you scale, and what is your targeted level of growth? Were looking at 200,000 downloads by the end of 2022. We have a B2B, B2C hybrid approach, really scaling through our relationships in the sports industry, athletic programs, sports organizations, and then also with sports performance wellness clubs. There are opportunities for us to complement the values of where fitness, wellness and performance reside, in bringing this next level of wellness performance and fitness from the neck up.

Who are your competitors, and what makes you different? This may sound clich, but it's not. Were looking to leverage, educate and advance the science of neuroplasticitythat the mind and the brain can change. In one sense, we're rooting for everyone that's showing we can make a difference in bettering people's mental and cognitive ability. That's one thing. On the other hand, I'd say from a user journey, user-cost perspective, the siloed space typically is when you have Calm or Headspace that are typically in the mindfulness or the cognitive training aspects of it. In general, the wellness and cognitive training apps would really be considered where the level of competition would be at.

Whats the unfair advantage that separates your company? There are a couple of things we think really separates us in a unique way. The expertise and lived experience aspects of what we have. Our chief scientific officer is Dr. Elkhonon Goldberg. He's one of the foremost leaders in the areas of brain function, one of the early pioneers of neuroplasticity in cognitive fitness. Also, to the uniqueness of what we're doing in really personalizing the betterment experience, we believe that's what neuroplasticity is really telling us is there's an opportunity to truly personalize how an individual can get better. We've created our mindset profile, which we really believe separates us in a really unique way in that we're discovering users unique mental framework as they come into the app. Then, we're customizing their in-app experience. Think about going to a high-end or elite training facility or a personal trainer. The whole goal is how to train in a way that best fits your unique makeup to get the best outcomes. We're building that into the app experience. We really believe this is a differentiator for us, and as we help people get better, it allows us to get smarter and to continue to personalize better at scale.

After Dr. Tommy Shavers suffered severe cognitive decline from football head injuries, he developed NESTRE as a model for self-recovery.

What milestone have you recently hit or will soon hit? We'll soon have our first live Neuro-Strength training rooms up in the market in mid-to-late January in Orlando in the Lake Nona Performance Club. The app will be in-market in late February, early March. So, Im really excited about getting really close to launch.

In what ways have you adapted to the COVID-19 pandemic? Our original go-to-market was with our NESTRE Neuro-Strength training facilities, and with the vision of being the first to scale mental and cognitive fitness and strength training facilities across the country. We're still looking to do that. We were literally coming back from finalizing one of our partnerships with a professional sports organization in March 2020 when the world shut down. Our vision and roadmap really pivoted, and it gave us an opportunity to look at the world differently in the sense of, How can we add this value in the landscape that isnt limited to face-to-face interaction? Our digital solution was further down on our roadmap, and so it allowed us to really reverse that and to bring our digital solution to the forefront to allow us to move forward. As weve gotten a little more stable, it's really given us an incredible opportunity to actually bring all of our solutions to market our NESTRE mindset profile, our NESTRE app and our NESTRE Neuro-Strength training facilities, and market in an integrative and standalone way. COVID presented some really unique challenges, but it's also given us unique opportunities to really think about how we help people get better, considering the landscape of the mental and cognitive challenges people are dealing with either from COVID or the pandemic. In general, we really see that mental and cognitive health is and will continue to be a premium moving forward.

Beyond the pandemic, what obstacles has your company had to overcome? Just being a startup. One of the things that can't be overlooked is the data shows less than 3% of all funding goes to founders of color or female founders. The challenge of raising capital, we've been fortunate to have a great opportunity to do that. But also, the uniqueness of combining the things we're doing at a really high level. We're taking serious science, innovation and technology in the sports place, both live and digital. Your typical startup is taking one thing to market in a really concise way. We believe being able to have three stand-alone and integrated solutions has been a challenge on the front-end, but will give us incredible positioning, leverage and strength as we get in the market and move forward.

What are the values that are core to your brand? The first is people. Our vision is to help build a better world with humans in mind. Everything we do is about people, it's people centric. It's built off my own personal lived experience. We know if we're helping people get better and increase quality of life, then we're being true to our mission and core values. The second is integrity with everything we do. This is a personal value that has become an organizational value. It really means to be sound. We really want to be true to who we are, true to what we do, sound in every way possible as we move forward. The third is what we refer to as confident humility. What we mean by confident humility is its this interplay between having the ability and the confidence to see the future before it happens. Being unafraid of risks. Really having an entrepreneur and innovative spirit, in the sense that just because you can't see it doesn't mean it's not there, right? We're really looking to move things forward in ways that traditionally have waited for solutions that take years, when people are saying, How can you help me now? Were really anchoring in this. We're confident in doing things that haven't been done before and unafraid of taking those types of approaches. At the same time, having the humility to understand we don't know what we don't know. There's constant room for growth. We really want to be a smart company, with this vision of having applied solutions, that as we're helping people get better we're getting smarter as we grow. We always want to have this learners spirit and mindset in the balance between the two of those things. We're fearless and we're mindful at the same time.

What does success ultimately look like for your company? I go back to our vision. Our vision is to help build a better world with the human in mind. We look down the line, three, four, five years, really being entrenched as a pioneer leader in the space of human development, human potential and mental health performance. Being a known company, an organization that's on the forefront of moving forward the science and the solutions to help people get better. If we're doing those things, we're heading in the right direction.

What should investors or customers know about youthe person, your life experiencesthat shows they can believe in you? First and foremost, this is personal. It's been a lived experience for me. I know what it's like to suffer and experience mental and cognitive challenges. I also know what its like to perform at the highest level, both mentally and cognitively. This is a space that not only is near and dear to me. I also have a personal passion, and I'm uniquely suited to navigate this space and at a high level. Also, just the ability to lead, inspire and to work with incredible people, with the team we've developed and brought around us. It's important to know the kind of leadership and the kind of team you have that can move a company like NESTRE forward and do it at a high level. I love what I do. There was a point in which I was told I wouldn't be able to function in the way I do now. Defying odds is built into my DNA, and I look forward to taking on this challenge.

As Dr. Tommy Shavers puts it, NESTRE is a performance, not a pathology, company, committed to 'change the narrative and the stigma' about mental health.

How does NESTRE help with mental health? Its a core part of our work. I had six to seven concussive blows within a three-week span that ended my career. The mental health and cognitive health challenges I experienced and suffered, along with the impairment decline, is really the core foundation of why we built this. The reason why we refer to ourselves as a strength company is because what neuroplasticity is saying is, whether it's pathology or performance, there's an ability to move toward better and that comes from the ability to strengthen what's there. What we've said is were a performance--not a pathology-company. Were training, not a treatment company. Were really trying to change the narrative and the stigma around this idea of mental health, as opposed to mental strength, mental strength training, or cognitive health and cognitive strength and cognitive sprint training. What it's doing is it's bringing us all together in saying no matter where you are, we all have an opportunity to get better and placing the person struggling with anxiety or stress and the person that's in the top 1% of the performance in the same community really helps us all to realize the human side of who we are. It really begins to destigmatize the narrative around it. We stay in this training space by saying, We're here for everyone as an opportunity to be able to get better. Mental health is a huge part of that for us, from a day-to-day basis, understanding the challenges in the sports world, but also an everyday lived experience. Its unfortunate that the current narrative is typically said that in order to embrace this, you have to embrace being broken in some way. What we're saying is: That's not the case. Mental health and mental strength is a part of all of our lived experiences. Everyone deals with mental and cognitive load on a daily basis. We really wanted to place all those individuals in the same community moving toward the same goal of getting better.

Do you have a favorite quote about leadership? Everything starts with being a CEO of self. I use that a lot with our team and individuals. That means everything: Leadership, accountability, wellness, self-care values. Another one is not taking for granted the privilege and power of influence.

Question? Comment? Story idea? Let us know at [emailprotected]

Read the original here:
NESTRE Believes Sport Performance Is From the Neck Up and Aims to Train the Mind and Brain Accordingly - SportTechie

Hyris Fully Embraces the Immunology Sector to Better Fight COVID-19 and Beyond, Presenting Its New, Disruptive T-Cell Test to the International…

LONDON, Dec. 15, 2021 (GLOBE NEWSWIRE) -- As the COVID-19 pandemic keeps causing concerns, with new variants spreading worldwide, it is now widely recognized that we must move beyond a "test&trace" only approach. World leaders and health institutions today aim to achieve high immunity rates among the population, facing the unprecedented challenge of a worldwide vaccination campaign against an emerging virus, for which no vaccine existed until a year ago.

"Alongside with our genetic tests to detect SARS-CoV-2 anywhere, and at any time, we knew that we had to put our knowledge at the service of vaccination campaigns even further, leveraging the versatility of our AI platform to deliver a new kind of immunology test." So says Stefano Lo Priore, Founder and CEO at Hyris, a global biotech company renowned for its innovative and inclusive approach to genetic analysis. Hyris offers a wide range of solutions to support the fight against COVID-19 worldwide. Several Medical professionals and decision-makers have already made use of the Hyris SystemTM to reliably detect the presence of all the main Variants of Concern.

As a key part of a long-term strategy to fight COVID-19, Hyris keeps supporting Immunology Research, now presenting its new test to detect the body's T Cell immune response to SARS-CoV-2 on 17 December 2021, at "A-WISH", Alicante-Winter Immunology Symposium in Health. Organized by the Spanish Society of Immunology (SEI) and the University of Alicante (UA), the "A-WISH" Symposium promotes the advancement of the study of immunology, infectious diseases and vaccinology as well as Life and Health Sciences. This first edition specifically aims to address strategies for the COVID-19 response and pandemic preparedness, the development of the vaccines against SARS-CoV-2 and the immunological response to infection and different COVID-19 vaccines.

"Until now, antibody testing has been considered the only tool to measure immunity to SARS-CoV-2," explains Isabella Della Noce, Chief Biologist at Hyris, "but individuals exposed to the virus or vaccinated do not necessarily develop or maintain antibody positivity. That is why we need to focus on T-Cells as they act together with antibodies to prevent pathogen spread and remove virus-infected cells. An individual negative to an antibody test could still be immune, thanks to responsive T-Cells. Therefore, measuring T-Cells response is a new disruptive approach to fight SARS-CoV-2."

The new Hyris T-Cells clinical Test was developed through exclusive agreements between Hyris and some illustrious healthcare scientific organizations, such as with Singapore Duke-NUS Medical School and New York Ichan School of Medicine at Mount Sinai, both well renowned worldwide for their publications and studies within the immunology and virology fields.

"This new test enables quick evaluation of T-cell immune responses in COVID-19 convalescent patients as well as vaccinated people, also indicating where patients are responsive due to vaccination, virus exposure or both,"specifies Lorenzo Colombo, Global Chief Technical Officer at Hyris. "And that's where PCR testing comes into the picture. Not only data show that PCR is fully comparable in accuracy and sensitivity with other assays traditionally used to measure the body's immune response, but it is more convenient and faster as a widely used diagnostic technology. This is indeed a new dimension for vaccine strategies."

This new test workflow has been already adopted by international research projects and committees, such as VACCELERATE, the European Program for the acceleration of phase 2 & 3 COVID-19 vaccine trials and the creation of a pan-European platform for clinical trial design and conduct, and the Spanish governmental Project Ene-Covid, the "Estudio Nacional de sero-Epidemiologa de la Infeccin por SARS-CoV-2 en Espaa".

"To support and validate vaccination campaigns worldwide, we need much greater access to accurate tests, especially in the Immunology field," concludes Lo Priore. "This disruptive approach can also be applied to other immunology areas, such as oncology or related to even more specific human pathogens. It can also focus strategically on specific patients' categories, such as, for example, immune-compromised, transplanted or cancer patients. Our immune system really is the perfect "source-code" to our knowledge, about how to take care of life."

The 2021 "A-WISH" Symposium will bring together a group of internationally recognized immunologists, microbiologists, molecular biologists, epidemiologists, virologists and professionals from a wide range of disciplines in the biomedical field to present and discuss the most recent results of top-tier immunology scientific research and innovations. Hyris will participate in the discussion, aiming to accelerate the development of new approaches to disease prevention.

Contact a Hyris expert to discover how to perform beyond your current diagnostic capability, atinfo@hyris.net.

Related Images

Image 1: Hyris presents its disruptive T-Cells test to detect the body's immune response to SARS-CoV-2.

A doctor holding a tablet showing the HYRIS bAPP

This content was issued through the press release distribution service at Newswire.com.

See more here:
Hyris Fully Embraces the Immunology Sector to Better Fight COVID-19 and Beyond, Presenting Its New, Disruptive T-Cell Test to the International...

Pfizer Augments Inflammation and Immunology Business with $6.7 Billion Buy – BioSpace

Pierre Suu/Getty Images

The share price of Arena Pharmaceuticalsnearly doubled in premarket trading after pharma giant Pfizer announced it was acquiring the company and its diverse portfolio of developmental and clinical assets, including a late-stage ulcerative colitis treatment, in an all-cash deal valued at approximately $6.7 billion.

Pfizer will acquireoutstanding shares of the company for $100 per share. Arenas stock closed at $49.94 on Friday, and the share price has soared to $95.95 in premarket trading after the announcement was made.

Mike Gladstone, president and general manager of Pfizers Inflammation and Immunology division, said the acquisition of Arena would complement the companys inflammation and immunology business. He said the Arena assets would provide hope for a better and more effective treatment for patients with debilitating immuno-inflammatory diseases.

Specifically, Pfizer is eying Utah-based Arenas experimental Crohns treatment etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator. Not only doesetrasimod showpotential in Crohnsbecause of its design to provide systemic and local effects on specific immune cell types, but the experimental drug can also potentiallytreat multiple immune-mediated inflammatory diseases, including ulcerative colitis, eosinophilic esophagitis, atopic dermatitis, and alopecia areata.

Currently, etrasimod is in two Phase III studies in ulcerative colitis, a Crohns disease study, and is moving into a late-stage program in atopic dermatitis.

In Phase II studies in ulcerative colitis, etrasimod showed promise. After 12 weeks, many patients showedpositive clinical responses, clinical remission, or endoscopic improvement. Additionally, data showed that patients in the study experienced sustained or improved effects up to week 46 an open-label extension. Etrasimod also demonstrated a favorable benefit/risk profile. Data from the Phase III studies are expected in 2022.

Last month, Arena announced it achieved target enrollment in its Phase II/III CULTIVATE Study A, designed to assess the efficacy, safety, and tolerability of oral etrasimod as a potential therapy for adult participants who have moderate to severe Crohns disease and are refractory or intolerant to at least one of the currently available therapies. Etrasimod is also in two Phase II programs in eosinophilic esophagitis and alopecia areata.

Utilizing Pfizers leading research and global development capabilities, we plan to accelerate the clinical development of etrasimod for patients with immuno-inflammatory diseases, Gladstone said in a statement.

In addition to etrasimod, Arenas pipeline includes two development-stage cardiovascular assets, temanogrel and APD418. Temanogrel is currently in Phase II development to treat microvascular obstruction and Raynauds phenomenon secondary to systemic sclerosis. APD418 is currently in a Phase II clinical trial for acute heart failure.

Arena President and Chief Executive Officer Amit D. Munshi expressed excitement regarding the planned acquisition. Munshi said the proposal recognizes Arenas potentially best-in-class S1P molecule and contribution to addressing unmet needs in immune-mediated inflammatory diseases. When the merger goes through, Munshi said Pfizers capabilities will accelerate the companys mission to bring those medications through the regulatory paths and to patients who need new options.

We believe this transaction represents the best next step for both patients and shareholders, Munshi said in a statement.

Featured Jobs on BioSpace

View post:
Pfizer Augments Inflammation and Immunology Business with $6.7 Billion Buy - BioSpace

Characterizing telemedicine use in clinical immunology and allergy in Canada before the COVID-19 pandemic – DocWire News

This article was originally published here

Allergy Asthma Clin Immunol. 2021 Dec 13;17(1):131. doi: 10.1186/s13223-021-00635-1.

ABSTRACT

RATIONALE: There exists a geographic barrier to access CIA care for patients who live in rural communities; telemedicine may bridge this gap in care. Herein we characterized the use of telemedicine in CIA at a population-based level and single centre.

METHODS: Before the COVID-19 pandemic, telemedicine care was provided via the Ontario Telemedicine Network (OTN) in Ontario, Canada. Descriptive data were collected from the OTN administrative database and from electronic medical records at a single academic centre during 2014 to 2019. The potential distance travelled and time saved by telemedicine visits were calculated using postal codes.

RESULTS: A total of 1298 telemedicine visits was conducted over OTN, with an average of 216 visits per year. Only 11% of the allergists/immunologists used telemedicine to provide care before the COVID-19 pandemic. In the single centre that provided the majority of the telemedicine care, 66% patients were female and the overall mean age was 46. The most common diagnosis was immunodeficiency (40%), followed by asthma (13%) and urticaria (11%). Most patients required at least one follow-up via telemedicine. The average potential two-way distance travelled per visit was 718 km and the average potential time travelled in total was 6.6 h.

CONCLUSION: Telemedicine was not widely used by allergists/immunologists in Ontario, Canada before the COVID-19 pandemic. It could offer a unique opportunity to connect patients who live in remote communities and allergists/immunologists who practice in urban centres in Canada. Independent of the current pandemic, our study further highlights the need for more physicians to adopt and continue telemedicine use as well as for healthcare agencies to support its use as a strategic priority once the pandemic is over.

PMID:34903277 | DOI:10.1186/s13223-021-00635-1

Read more here:
Characterizing telemedicine use in clinical immunology and allergy in Canada before the COVID-19 pandemic - DocWire News

Corbett Named One of Time’s Heroes of the Year | Newsroom – UNC Health and UNC School of Medicine

Kizzmekia Corbett, PhD, a vaccine scientist at the National Institutes of Health and UNC School of Medicine Alumna, was named one of Time magazines Heroes of the Year for her work on developing a COVID-19 vaccine.

Kizzmekia Corbett, a 2014 graduate of the UNC School of Medicine Microbiology and Immunology PhD Program, has been named among Time Magazines 2021 Heroes of the Year.

Times 2021 Heroes of the Year recognition honors the scientists whose work produced COVID-19 vaccines, including Corbett; Barney Graham, MD, PhD, former deputy director of the NIH Vaccine Research Center; Katalin Kariko, PhD, biochemist and adjunct professor of neurosurgery at the University of Pennsylvania Perelman School of Medicine; and Drew Weissman, MD, PhD, Roberts Family Professor in Vaccine Research in the Perelman School of Medicine.

As a student in the UNC School of Medicine, Corbetts mentor was Aravinda de Silva, PhD, professor in the UNC Department of Microbiology and Immunology. Corbett focused on vaccine development and studied dengue virus at UNC. She won an off-campus dissertation fellowship from the UNC Graduate School and conducted research in Sri Lanka, and she was involved in extracurricular activities, including serving as a representative on the UNC Student Congress, a delegate to the UNC System Association of Student Governments, a staff member in the Honor System Attorney Generals office, and as a member of the science policy advisory group.

In 2014, Corbett was appointed to serve as the team lead for coronavirus research within the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Centers Viral Pathogenesis Laboratory. Corbetts team partnered with Moderna to create a vaccine using state of the art mRNA technology in. The FDA cleared Modernas vaccine for emergency use in December 2020.

Today, Corbett is an assistant professor of immunology and infectious diseases at the Harvard T.H. Chan School of Public Health.

Her work has garnered several prestigious awards, including the Benjamin Franklin Next Gen Award and the Salzman Memorial Award in Virology. Additionally, the Board of Commissioners in Corbetts hometown of Hillsborough, North Carolina, declared Jan. 12, 2021, as Kizzmekia Kizzy Corbett Day.

In February 2021, Corbett was named to Time Magazines 2021 TIME100 Next List, and in May 2021, Corbett and Anthony Fauci, MD, director of the NIAID, delivered UNC-Chapel Hills Spring Commencement Address.

Original post:
Corbett Named One of Time's Heroes of the Year | Newsroom - UNC Health and UNC School of Medicine

Luke O’Neill says booster helped to ensure he only got ‘mild’ Covid – The Irish Times

Immunology professor Luke ONeill has encouraged people to get vaccinated, saying he is only experiencing mild symptoms of Covid-19 as a result of having beenjabbed.

Speaking to The Irish Times on Monday evening, Prof ONeill said that he was deemed a close contact of a confirmed case, and the second HSE antigen test he took on Friday was positive.

On Saturday, he got a PCR test to confirm the result, which came back positive on Sunday.

Im pretty healthy because of the vaccine... vaccines prevent severe disease, and Ive got very mild symptoms, thank God, he said.

People who are fully-vaccinated should not be too worried about Covid, according to Prof ONeill. The virus might grow in your nose... The vaccine is really working to protect your lungs, not so good at your nose, because the immune system cant get there. Thats whats happened to me, its stayed in my nose, and its like a cold.

However, he said people who are immunocompromised are most at risk at the moment, and he was glad to see the National Immunisation Advisory Committee (Niac) recommending a fourth dose to people in this category.

We worry about the immunocompromised. These are people who are on chemotherapy, or some other reason their immune system isnt working properly. They need the best possible chance at protection.

He said that now that we know the vaccines are safe, we should utilise them as much as possible. Niac have said immunocompromised people should get a forth dose three months after their third.

Prof ONeill added that children should hopefully get vaccinated soon, with the first shipment of childrens vaccines arriving into Ireland this week.

It was especially important to vaccinate children who were immunocompromised as they had no protection yet, he said.

He also thought that offering a booster dose to everyone three months after their second dose, regardless of what vaccine they received, was a wise move ahead of the increased socialisation around Christmas. Minister for Health Stephen Donnelly announced this change on Monday evening on foot of Niacs recommendation.

There was good evidence published that three months works basically, you get a good response... theres no need to wait for five months.

Omicron has changed the situation, he added, and the Government and Niac had responded to it appropriately.

He doesnt think that everyone will need a forth dose, but added that it was hard to know yet. It might be offered to older people... younger people usually have a stronger immune system.

Earlier, Prof ONeill said he would be quadruply vaccinated, having had the booster on Thursday after his two-shot vaccine, and then testing positive for Covid at the weekend.

Now is the time to boost as many as possible, he told RT Radio Ones Today with Claire Byrne show.

He said that, even if symptoms from the Omicron variant were milder, as research had indicated, there could still be a number of people who ended up in hospital and that would put pressure on the health system.

However, it was still uncertain how strong the level of infection was , he said, which was why it was important for everyone to be boosted.

This article was amended on December 14th, 2021

Read the original:
Luke O'Neill says booster helped to ensure he only got 'mild' Covid - The Irish Times

US FDA Approves Pfizer’s XELJANZ (tofacitinib) for the Treatment of Active Ankylosing Spondylitis | Small Molecules | News Channels -…

DetailsCategory: Small MoleculesPublished on Wednesday, 15 December 2021 10:02Hits: 300

NEW YORK, NY, USA I December 14, 2021 I Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for XELJANZ / XELJANZ XR (tofacitinib) for the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.

We are proud to offer XELJANZ, a treatment option for ankylosing spondylitis that does not require an injection or an infusion, to treat this debilitating and chronic immuno-inflammatory disease, said Mike Gladstone, Global President, Inflammation & Immunology, Pfizer. This regulatory approval affirms the clinical value and versatility of XELJANZ, the first and only Janus kinase (JAK) inhibitor approved for five indications in the United States for the treatment of patients with certain immuno-inflammatory conditions.

The approval of XELJANZ for AS is based on data from a Phase 3, multicenter, randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of tofacitinib 5 mg twice daily versus placebo in 269 adult patients living with active AS. The study met its primary endpoint showing that at week 16, the percentage of patients achieving an Assessment in SpondyloArthritis international Society (ASAS)20 response was significantly greater with tofacitinib (56.4%, n= 75) versus placebo (29.4%, n=40) (p<0.0001). In addition, the percentage of patients achieving an ASAS40 response was significantly greater with tofacitinib (40.6%, n=54) versus placebo (12.5%, n=17) (p<0.0001), a key secondary endpoint of the study.1 ASAS20/40 are used for defining improvement or response to treatment.2 The safety profile observed in patients with AS treated with XELJANZ was consistent with the safety profile observed in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients.

Ankylosing spondylitis, a type of arthritis that causes inflammation in certain parts of the spine, affects more than 350,000 people in the U.S.3 This disease often occurs in early adulthood and causes pain, swelling and possibly restricted mobility,4 said Steven Taylor, Executive Vice President, Mission and Strategic Initiatives of the Arthritis Foundation. With this approval, physicians and patients now have an additional oral treatment option that can help address this chronic and often progressive disease.

About XELJANZ (tofacitinib)

XELJANZ is the first and only oral JAK inhibitor approved in the United States in five indications. XELJANZ is indicated in patients who have had an inadequate response or intolerance to one or more TNF blockers: in adults with active AS, adults with moderately to severely active RA, active PsA, moderately to severe active ulcerative colitis (UC) and in children two and older with active polyarticular course juvenile idiopathic arthritis (pcJIA).

XELJANZ has been studied in more than 50 clinical trials worldwide, including more than 20 trials in RA patients, and prescribed to over 300,000 adult patients (the majority of whom were RA patients) worldwide since 2012.5,6,7 As the developer of XELJANZ, Pfizer is committed to advancing the science of JAK inhibition and enhancing understanding of this medicine through robust clinical development programs in the treatment of immuno-inflammatory conditions.

Earlier this month, the FDA updated the prescribing information for XELJANZ and included a new boxed warning for major adverse cardiovascular events and updated boxed warnings regarding mortality, malignancies and thrombosis (with corresponding updates to applicable warnings and precautions). In addition, indications for the treatment of adults with moderately to severely active RA or active PsA, and patients who are two years of age and older with active pcJIA were revised to require inadequate response or intolerance to one or more TNF blockers.

About Ankylosing Spondylitis

Ankylosing Spondylitis is a chronic, inflammatory disease that affects men and women in early adulthood. The onset of symptoms usually occurs before the age of 30 and seldom occur after the age of 45. Symptoms of AS include chronic pain and stiffness in the back and hips for those living with the disease and can negatively impact health-related quality of life. Over time, some patients may experience fusion of the vertebrae in the spinal column.8 According to studies, more than 350,000 people live with AS in the United States.3

INDICATIONS

Rheumatoid Arthritis

Psoriatic Arthritis

Ankylosing Spondylitis

Ulcerative Colitis

Polyarticular Course Juvenile Idiopathic Arthritis

Please see full Prescribing Information, including BOXED WARNING for XELJANZ available at: http://www.xeljanzpi.com.

About Pfizer Inflammation & Immunology

At Pfizer Inflammation & Immunology, we strive to deliver breakthroughs that enable freedom from day-to-day suffering for people living with autoimmune and chronic inflammatory diseases, which can be debilitating, disfiguring and distressing, dramatically affecting what they can do. With a focus on Rheumatology, Gastroenterology and Medical Dermatology, our current portfolio of approved medicines and investigational molecules spans multiple action and delivery mechanisms, from topicals to small molecules, biologics and biosimilars. Our differentiated R&D approach resulted in one of the broadest pipelines in the industry, where we purposefully match molecules to diseases where we believe they can make the biggest difference. Building on our decades-long commitment and pioneering science, we continue to advance the standard of care for patients with these debilitating diseases and are working hand-in-hand with patients, caregivers and the broader healthcare community on healthcare solutions for the many challenges of managing chronic inflammatory diseases, allowing patients to live their best lives.

To learn more, visit http://www.pfizer.com/science/immunology-inflammation.

Pfizer Inc.: Breakthroughs that change patients lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at http://www.pfizer.com. In addition, to learn more, please visit us on http://www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

1 Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, Wang L, Wu J, Menon S, Wang C, Dina O, Fallon L, Kanik KS, van der Heijde D. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021 Apr 27;80(8):100413. doi: 10.1136/annrheumdis-2020-219601. Epub ahead of print. PMID: 33906853; PMCID: PMC8292568. 2 Landew R, van Tubergen A. Clinical Tools to Assess and Monitor Spondyloarthritis. Curr Rheumatol Rep. 2015;17(7):47. doi:10.1007/s11926-015-0522-3 3 Strand V, et al. Prevalence of axial spondyloarthritis in United States rheumatology practices: Assessment of SpondyloArthritis International Society criteria versus rheumatology expert clinical diagnosis. Arthritis Care Res (Hoboken ). 2013;65:1299-1306. doi:10.1002/acr.21994 4 Johns Hopkins Arthritis Center. Ankylosing Spondylitis. Accessed December 1, 2021. https://www.hopkinsarthritis.org/arthritis-info/ankylosing-spondylitis 5 Pfizer Data on File. XELJANZ Worldwide Registration Status. 6 ClinicalTrials.gov. Tofacitinib RA Studies. Accessed June 25, 2020. 7 Pfizer. Data on File. Tofa Counts. April 2019 8 University of Maryland Medical Center. A Patients Guide to AS. Accessed August 2021. Available at: https://www.umms.org/ummc/health-services/orthopedics/services/spine/patient-guides/ankylosing-spondylitis

SOURCE: Pfizer

View post:
US FDA Approves Pfizer's XELJANZ (tofacitinib) for the Treatment of Active Ankylosing Spondylitis | Small Molecules | News Channels -...